Kin­tara of­fers peek at mid-stage da­ta in re­lapsed glioblas­toma pa­tients; Jazz wins quick ap­proval for pe­di­atric can­cer drug

Among the dozens of can­cer types, glioblas­toma has proven one of the hard­est to crack with lit­tle clin­i­cal suc­cess over the years. Now, a San Diego biotech is rolling out mid-stage da­ta it claims could be point­ing its drug in the right di­rec­tion in re­lapsed pa­tients. But there are sev­er­al caveats.

A high dose of Kin­tara’s VAL-083 spurred a me­di­an OS of 8 months in pa­tients with re­cur­rent glioblas­toma who had been pre­vi­ous­ly treat­ed with chemother­a­py temo­zolo­mide, ac­cord­ing to topline da­ta from an open-la­bel Phase II study con­duct­ed at MD An­der­son Can­cer Cen­ter in Hous­ton.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.